TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05914675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letermovir
Description: For enrolled patients, Letermovir would be administered at a dose of 480 mg per day (or 240 mg per day in patients taking cyclosporine). The regimen would start between +7\~+14d after transplantation. The total duration of dosing was approximately 100 days or 14 weeks.
Study: NCT05489419

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multimodal Prehabilitation
Description: Physical and cardiopulmonary training, personalized nutrition and treatment of anxiety and depression.
Study: NCT05135156

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Investigator-designed lung transplant education resource (Research Intervention)
Description: Participants will access the investigator-designed educational resource via their login to a secure website. After two weeks, participants will gain access to the publicly available website (attention control) and will have an additional two weeks of access to both of these resources.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Publicly available transplant education resource (Attention Control)
Description: Participants will access the publicly available education resource via their login to a secure website. After two weeks, participants will gain access to the investigator-designed educational resource (research intervention) and will have an additional two weeks of access to both of these resources.
Study: NCT05635097

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Motivational Interviewing counseling on the Mediterranean diet and weight checks at regular intervals
Description: Each participant will meet virtually on Zoom with the DNP project leader and receive 1:1 counseling on pairing the Repnho smart scale and tape measure with the Renpho application. The expectations of the weight management program will be explained in detail during the first session, which will last one hour (session one= week zero). The weight loss goal will be at least 1-2 pounds per week as recommended by the Centers for Disease Control and Prevention (CDC) (2022).
Study: NCT04720963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: intranasal remimazolam

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Distilled water for injection
Description: intranasal distilled water for injection
Study: NCT06219018

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical grade honey formulation (MGH) (L-Mesitran®)
Description: daily application of 5 grams (with applicator)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical grade honey formulation (MGH) (L-Mesitran®)
Description: daily application of 5 grams (with applicator)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical grade honey formulation (MGH) (L-Mesitran®)
Description: daily application of 5 grams (with applicator)
Study: NCT05083806

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Multispectral Optoacoustic Tomography
Description: Non-invasive optoacoustic imaging of muscular structure

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Multispectral Optoacoustic Tomography
Description: Non-invasive optoacoustic imaging of muscular structure
Study: NCT04720963

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Intranasal dexmedetomidine
Study: NCT05816148

Intervention type: OTHER
Intervention: Questionnaire survey
Description: On leisure physical activity, barriers to physical activity and quality of life.
Study: NCT02293525

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ReLeaf catheter
Description: Continuous infusion rate 10ml/hr (5ml/side)

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: ReLeaf catheter
Description: Continuous infusion rate 10ml/hr (5ml/side)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Patient-controlled analgesia (PCA) at 1mg every 6 minutes with a 4 hour lock out after 30mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Morphine
Description: Patient-controlled analgesia (PCA) at 1mg every 6 minutes with a 4 hour lock out after 30mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: 10mg every 4-6 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxycodone
Description: 10mg every 4-6 hours
Study: NCT04466618

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline infused during the study

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Exendin-9,39
Description: Exendin-9,39 infused during the study

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Saline + Intralipid/Heparin
Description: Saline infused during acute insulin resistance

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Exendin-9,39 + Intralipid/Heparin
Description: Exendin-9,39 infused during acute insulin resistance
Study: NCT04769713

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hepatic Hilar Nerve Block Needle placement
Description: Placement of a needle within 2cm of the portal vein bifurcation along its anterior surface for injection of nerve block agent (for nerve block) or saline (placebo) under US or CT guidance.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hepatic Hilar Nerve Block Needle placement
Description: Placement of a needle within 2cm of the portal vein bifurcation along its anterior surface for injection of nerve block agent (for nerve block) or saline (placebo) under US or CT guidance.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Hepatic Hilar Nerve Block Needle placement
Description: Placement of a needle within 2cm of the portal vein bifurcation along its anterior surface for injection of nerve block agent (for nerve block) or saline (placebo) under US or CT guidance.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Hepatic Hilar Nerve Block Needle placement
Description: Placement of a needle within 2cm of the portal vein bifurcation along its anterior surface for injection of nerve block agent (for nerve block) or saline (placebo) under US or CT guidance.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injection of Ropivacaine in the hepatic hilum for the hepatic hilar nerve block
Description: Injection of 15 ml 0.5% Ropivacaine at the hepatic hilum along the anterior surface of the portal vein within 2cm of the bifurcation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injection of Ropivacaine in the hepatic hilum for the hepatic hilar nerve block
Description: Injection of 15 ml 0.5% Ropivacaine at the hepatic hilum along the anterior surface of the portal vein within 2cm of the bifurcation.
Study: NCT05083806

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multispectral Optoacoustic Tomography
Description: Non-invasive optoacoustic imaging of muscular structure
Study: NCT05537649

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oatmeal porridge
Description: Investigation of the impact of enzymatic modification of the molecular structure of starch by amylomaltase on the postprandial glycemic responses of an oatmeal porridge.
Study: NCT05051124

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Delivery of Medications
Description: The study team will adopt a novel approach of extending beyond the use of peer support in the clinical setting and implement door-to-door peer delivery of medications within patients' communities

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Information Technology (HIT) Platform
Description: To support peer delivery, the study team will use a HIT platform that performs 4 core functions: 1) tailored counseling strategies through decision support; 2) teleconsultation support for clinician-peer-patient interactions; 3) tracking medication refills to enhance accountability of the peer delivery process; and 4) analytics to improve medication supply chain by generating patient-level drug consumption data. This is an innovative use of HIT to accomplish these functions to support medication adherence.
Study: NCT05404698

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: EX: 30 min of aerobic exercise (3/10 Borg scale) during hemodialysis treatment (between 30 min and 3h of treatment).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: CONT: participants will receive hemodialysis treatment only (usual care)
Study: NCT04877249

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Split-belt treadmill training
Description: 1. Split-belt gait training without or with any resistance, 2. Facilitating the knee extension during the terminal swing phase of gait cycle to identify the impact on the propulsive force generation of paretic leg

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Split-belt treadmill training
Description: 1. Split-belt gait training without or with any resistance, 2. Facilitating the knee extension during the terminal swing phase of gait cycle to identify the impact on the propulsive force generation of paretic leg
Study: NCT06257641

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-intensity Mediterranean diet intervention
Description: Dietary education for the adoption of the Mediterranean diet, with monthly monitoring - mostly online - by nutritionists with experience in the field. Patients will be given 500 ml of extra virgin olive oil per week and informative material about the Mediterranean diet, as well as recipes and weekly menus.
Study: NCT05764590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP-306
Description: A blood phosphorus lowering drug with a novel mechanism

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevelamer Carbonate
Description: A phosphate binder
Study: NCT05156645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCTA01 and SCTA01C
Description: Diluted by 0.9% normal saline
Study: NCT05472519

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: blood samples
Description: Only one visit for each participant: A large majority of visits will be part of patients' usual care.~* Medical examination : weight, gender, blood pressure, medical history~* Blood samples : 1 EDTA tube (3 mL) for CBC, 3 heparin tubes (3 × 7 mL) for frozen PBMC, 1 EDTA tube (3 mL) for frozen plasma

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: blood samples
Description: Only one visit for each participant: A large majority of visits will be part of patients' usual care.~* Medical examination : weight, gender, blood pressure, medical history~* Blood samples : 1 EDTA tube (3 mL) for CBC, 3 heparin tubes (3 × 7 mL) for frozen PBMC, 1 EDTA tube (3 mL) for frozen plasma

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: blood samples
Description: Only one visit for each participant:~* Medical examination : weight, gender, blood pressure, medical history~* Blood samples : 1 EDTA tube (3 mL) for CBC, 3 heparin tubes (3 × 7 mL) for frozen PBMC, 1 EDTA tube (3 mL) for frozen plasma

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: blood samples
Description: Only one visit for each participant:~* Medical examination : weight, gender, blood pressure, medical history~* Blood samples : 1 EDTA tube (3 mL) for CBC, 3 heparin tubes (3 × 7 mL) for frozen PBMC, 1 EDTA tube (3 mL) for frozen plasma
Study: NCT05156645

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Diluted by 0.9% normal saline
Study: NCT06336278

Intervention type: DIAGNOSTIC_TEST
Intervention: Pressure Algometer
Description: Pressure algometer is used to detect pain pressure treshold.

Intervention type: DIAGNOSTIC_TEST
Intervention: Pressure Algometer
Description: Pressure algometer is used to detect pain pressure treshold.
Study: NCT06182384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1314
Description: Receive a single dose of 240mg SHR-1314 at every period (First period：1mL AI, injection two needles. Second period: 2mL AI, injection one needle).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1314
Description: Receive a single dose of 240mg SHR-1314 at every period (First period：2mL AI, injection one needle. Second period: 1mL AI, injection two needles).
Study: NCT05183321

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: periodontal therapy
Description: periodontal cleaning
Study: NCT05641714

Intervention type: OTHER
Intervention: L test
Description: The test includes standing up from a chair, walking in a straight line for 3 m, turning to the right, walking in a straight line for 7 m, turning around, walking back 7 m along the same line, turning to the left, walk 3 m in a straight line to the chair, and then sit down.
Study: NCT05527847

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peers LEAD
Description: Two group session focusing on beliefs about medicines and diabetes, discrimination/mistrust, and communication with providers, and 2 peer-based phone calls from Ambassadors to occur weekly for weeks 3-8, then bi-weekly for weeks 9-12.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HLWD
Description: Weekly group sessions for two months. Sessions will last up to 2.5 hours and focus on a different diabetes self-management topic.
Study: NCT05641714

Intervention type: OTHER
Intervention: L test
Description: The test includes standing up from a chair, walking in a straight line for 3 m, turning to the right, walking in a straight line for 7 m, turning around, walking back 7 m along the same line, turning to the left, walk 3 m in a straight line to the chair, and then sit down.

Intervention type: OTHER
Intervention: Timed Up and Go test
Description: The test requires the individual to stand up from an armed chair, walk 3m, turn around, walk back to the armed chair, and sit down again.

Intervention type: OTHER
Intervention: 10 meter walk test
Description: In the test, the clinician measures the time taken to walk a distance of 10 m from a standing position. Participants are asked to walk along a 14 m long walkway.

Intervention type: OTHER
Intervention: Six Minute Walk Test
Description: This test measures the distance (in m) that an individual is able to walk at a comfortable speed for 6 minutes. Starting from a standing position, participants walk continuously around two pylons placed 30 m apart for 6 minutes. The distance is recorded end of the test.

Intervention type: OTHER
Intervention: The timed 360° turn test
Description: Each participant turns around in place in a standing position for both sides.
Study: NCT05694533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INDV-2000
Description: Capsules administered orally twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam syrup administered orally on Days 1 and 15
Study: NCT05527847

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HLWD
Description: Weekly group sessions for two months. Sessions will last up to 2.5 hours and focus on a different diabetes self-management topic.
Study: NCT06183619

Intervention type: PROCEDURE
Intervention: Pulmonary vein isolation plus superior vena cava isolation
Description: Pulmonary vein isolation plus superior vena cava isolation

Intervention type: PROCEDURE
Intervention: Pulmonary vein isolation
Description: Pulmonary vein isolation only
Study: NCT04687748

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electromographic Biofeedback
Description: Surface EMG biofeedback is an adjunct therapy to standard exercise regime for increasing muscle strength. Electromyographic biofeedback is a specific form of biofeedback. The device records muscle activity through application of vaginal probe will be inserted in vagina and the reference surface electrode would be placed over the right anterior superior iliac spine.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PFM exercises
Description: Patients would be advised to maximally contract the pelvic floor muscles as forcefully a possible for about 5 seconds. Three attempts would be made with 40 seconds rest in between each contraction. The exercises would be performed with the patient initially in supine position, with hip and knee flexed at 30 and 90 degrees.
Study: NCT05755217

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dark chocolate
Description: Single oral dose of 1g/kg of dark chocolate (70% cocoa).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: White chocolate
Description: Single oral dose of 1g/kg of white chocolate (4% cocoa).
Study: NCT06347770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiotic Blend Oral Tablet
Description: In our study, forty pregnant women were randomly assigned to the probiotic group, and the rest were assigned to the control group. After enrollment, pregnant women in the probiotic group received a combination of living Bifidobacterium longum (5 #106 CFU) by Neimengu Shuangqi Pharmaceutical Co., Ltd. Pregnant individuals in the probiotic group were administered four tablets three times a day (2 g/d) for seven days before surgery until the fourth day after surgery.
Study: NCT05864885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minoxidil
Description: Topical formulation applied once a day.
Study: NCT05428592

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LVRNA009
Description: 50μg /0.5 mL/Vial/person

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CoronaVac®
Description: 0.5 mL/Vial, 0.5mL per human dose containing 600SU of inactivated SARS-CoV-2 antigen
Study: NCT06294483

Intervention type: DIAGNOSTIC_TEST
Intervention: CBC
Description: Is used to detect haematological indices (mean platelet volume, platelet lymphocyte ratio and neutrophil lymphocyte ratio) and its relation to disease activity

Intervention type: DIAGNOSTIC_TEST
Intervention: CBC
Description: Is used to detect haematological indices (mean platelet volume, platelet lymphocyte ratio and neutrophil lymphocyte ratio) and its relation to disease activity

Intervention type: DIAGNOSTIC_TEST
Intervention: Antinuclear Antibody tests (ANA)
Description: To be tool in diagnosis of SLE

Intervention type: DIAGNOSTIC_TEST
Intervention: Antinuclear Antibody tests (ANA)
Description: To be tool in diagnosis of SLE

Intervention type: DIAGNOSTIC_TEST
Intervention: Rest of ANA profile
Description: As tool of diagnosis of SLE

Intervention type: DIAGNOSTIC_TEST
Intervention: Rest of ANA profile
Description: As tool of diagnosis of SLE

Intervention type: DIAGNOSTIC_TEST
Intervention: C3 and C4 complement level.
Description: As method of detection of acute acivity of SLE

Intervention type: DIAGNOSTIC_TEST
Intervention: C3 and C4 complement level.
Description: As method of detection of acute acivity of SLE

Intervention type: DIAGNOSTIC_TEST
Intervention: Anti phospholipid marker
Description: To detect antiphospholipid syndrome if there is sign of thrombosis

Intervention type: DIAGNOSTIC_TEST
Intervention: Anti phospholipid marker
Description: To detect antiphospholipid syndrome if there is sign of thrombosis

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum creatinine and Alb/create ratio
Description: To detct complication of disease on kidney
Study: NCT06361615

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Single-Task
Description: Single-task (ST) training group developed an exercise program based on Functional Exercise Circuit (FEC) protocol. This exercise program has been published previously12, which considered 15 different exercises in a functional exercise circuit.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dual-Task
Description: DT training (multicomponent physical exercise + cognitive tasks)
Study: NCT03696485

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCM-010
Description: SCM-010 is comprised of adipose derived expanded mesenchymal cells (ADSC), suspended in Plasma-Lyte and intended for intrathecal (IT) administration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCM-010
Description: SCM-010 is comprised of adipose derived expanded mesenchymal cells (ADSC), suspended in Plasma-Lyte and intended for intrathecal (IT) administration.
Study: NCT05209711

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Femoral nerve block under ultrasound control with a electrostimulator peripheral nerves 7.5 ml 1% lidocaine
Description: Following the ultrasound visualization of the femoral nerve, a insulated injection needle was connected to the nerve stimulator . Under ultrasound visualization guidance, the needle of the electronic nerve stimulator was positioned at the femoral nerve (in plane) from its lateral side at a slightly superior position . A marker for LA introduction was the visualization of the needle end near the nerve, and a positive muscular response . Subsequently, the introduction of LA solution was initiated (7.5 ml 1% lidocaine).If LA was spreading from the lateral side down to the nerve, then the needle was replaced to the upper point of the nerve and the rest of LA was introduced, and vice versa . The presence of a complete and incomplete spread of LA along the entire circumference of the nerve was assessed. Correspondingly, if the anesthetic was spreading upwardly, the needle would be downwardly replaced.~In addition, a sciatic nerve block is performed.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Femoral nerve blockade under ultrasound control without a peripheral nerve stimulator 7.5 ml 1% lidocaine
Description: Under ultrasound visualization guidance, the needle owas positioned at the femoral nerve (in plane) from its lateral side at a slightly superior position . A marker for LA introduction was the visualization of the needle end near the nerve. Subsequently, the introduction of LA solution was initiated. The position of the needle was corrected 1-2 times according to the type of anesthetic spread. If LA was spreading from the lateral side down to the nerve, then the needle was replaced to the upper point of the nerve and the rest of LA was introduced, and vice versa . The presence of a complete and incomplete spread of LA (7.5 ml 1% lidocaine) along the entire circumference of the nerve was assessed. Correspondingly, if the anesthetic was spreading upwardly, the needle would be downwardly replaced.~In addition, a sciatic nerve block is performed.
Study: NCT05818410

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prosthetic device (Lunaris)
Description: Participants with an amputation will conduct experiments with the prosthetic device

Intervention type: OTHER
Group type: OTHER
Intervention: No prosthetic device
Description: Able-bodied individuals will conduct experiments to enable comparison with the participants with amputation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prosthetic device (Sach foot)
Description: Participants with an amputation will conduct experiments with the prosthetic device